bih.button.backtotop.text
BROWSE BY TEST NAME
#
%
1
2
3
5
8
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code (รหัสการทดสอบ):
090-31-2761-01

Order Name (ชื่อการทดสอบ):
Anticardiolipin IgA **

 
Specimen / Container (สิ่งส่งตรวจ/ภาชนะ):
Blood/ Plain blood (Red top) 6 mL, 1 tube
 
Turnaround Time (ระยะเวลารอผล):
Received specimen to report within 7-10 days
(exception for official holidays)
 
Useful For (ประโยชน์การทดสอบ):
Diagnosis of Anti-phospholipid syndrome (APS) in the suspected patient.
 
Methodology (วิธีการทดสอบ):
Enzyme-linked Immunosorbent Assay (ELISA)
 
AliasesName (ชื่อเรียกอื่นๆ) :
Beta-2 GP1 Ab, IgA 
Beta-2 Glycoprotein 1 antibodies, IgA
 
 
 
Test Code (รหัสการทดสอบ):
090-31-2761-01

Order Name (ชื่อการทดสอบ):
Anticardiolipin IgA **

 
Collection Specimen Or Container (สิ่งส่งตรวจ/ภาชนะ):
Blood/ Plain blood (Red top) 6 mL, 1 tube
 
Specimen Testing Type (สิ่งส่งตรวจที่ใช้ในการทดสอบ):
Serum, minimum volume 2 mL
 
Sub Mission Container (ภาชนะส่งตรวจ):
Plastic tube
 
Rejection Criteria (เกณฑ์ปฏิเสธสิ่งส่งตรวจ):
Hemolysis: Mild OK, Gross reject
Lipemia: Mild OK, Gross reject
Icteric: Mild OK, Gross reject
 
Specimen Stabillity (ความคงตัวของสิ่งส่งตรวจ):
Specimen Type Temperature Time
Serum Refrigerated, 2oC to 8oC 14 days
 
 
 
Test Code (รหัสการทดสอบ):
090-31-2761-01

Order Name (ชื่อการทดสอบ):
Anticardiolipin IgA **

 
Method detail (วิธีการทดสอบ):
Enzyme-linked Immunosorbent Assay (ELISA)
 
Schedule (ตารางการทดสอบ):
N/A **Sent Out to Chulalongkorn
 
Turnaround Time (ระยะเวลารอผล):
Received specimen to report within 7-10 days
(exception for official holidays)
 
Performing Location (หน่วยงานที่ทำการทดสอบ):
Chulalongkorn
Referral Lab Services, Laboratory Department 14160-2
 
 
 
Test Code (รหัสการทดสอบ):
090-31-2761-01

Order Name (ชื่อการทดสอบ):
Anticardiolipin IgA **

 
 
Clinical Information (ข้อมูลทางคลินิก):
Anti-phospholipid syndrome (APS), also called Hughes syndrome, is an autoimmune disease which is characterised by thrombophilia. Cumulative haematological signs are mainly venous (37%) or arterial (27-49%) thrombosis, haemocytopenia (30-38%), pregnancy complications (55-74%), neurological failures (66%) and cardiological (27%), pulmonary (20-30%) or cutaneous (40%) tissue damage due to the above-mentioned circulatory disorders.
APS is an immunocoagulopathy and the most frequently acquired hypercoagulability. 82% of APS
patients are women and 18% men. Around 10% of APS cases are familial.  APS is divided into primary APS (pAPS) and secondary APS (sAPS). These are characterised by the same haematological immune responses. In sAPS, however, they occur during the course of the disease as secondary reactions, most frequently in connection with rheumatic diseases (e.g. SLE). 
According to the "International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) 2006 " the presence of anti-cardiolipin antibodies is a serological criterion in APS diagnostics. ACA have a high prevalence of 60 to 90% (ACA-IgG 44%, ACA-IgM 12%, ACA IgG/IgM 88%) and persist for more than 12 weeks in APS patients. ACA can be found in the serum of 15 to 30% of sAPS patients. In persons with thrombosis in their anamnesis the prevalence is 20% to 30%. 
 
Reference Value (ค่าอ้างอิง):
Negative < 12 PL IgA U/ml